We are excited to announce the publication of an important collaborative study with the Newcastle Fibrosis Research Group where we applied our precision-cut liver slice (PCLS) bioreactor technology to discover a naturally occurring mechanism that guards against the unhealthy build-up of fat in hepatocytes which affects up to 1 billion people worldwide and can lead to chronic liver disease and/or development of liver cancer.
The paper published on July 7th 2021 by the front-line liver research journal HEPATOLOGY describes a process called lipophagy which involves the autophagic degradation of lipid droplets. The novelty of the work was the discovery that a lipid-droplet binding protein Perilipin-3 (Plin3) is critical for the assembly of autophagic machinery at lipid droplets, for activation of lipophagy and prevention of inflammation. The study went further to show this process is dependent on phosphorylation of Plin3 which unlocks the possibility to therapeutically stimulate lipid degradation in hepatocytes to prevent non-alcoholic fatty liver disease (NAFLD).
The paper also demonstrates exciting new pre-clinical utilities of FibroFind's PCLS platform to model NAFLD including efficient genetic manipulation of hepatocytes using AAV-shRNA vectors that allows for targeted knockdown of gene expression within intact liver tissue. FibroFind looks forward to employing these technological advances as part of its growing portfolio of services to clients as well as in its future research operations.
We are able to do both liver and kidney PCS in this context, although we have not yet published any of our kidney data due to a patent filing. In addition, we also offer IPF lung PCS.
Click HERE to read the full article published on open access licence.